Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1989 Oct;57(10):3257–3258. doi: 10.1128/iai.57.10.3257-3258.1989

Efficacy of interleukin-1 beta against systemic Candida albicans infections in normal and immunosuppressed mice.

R A Pecyk 1, E B Fraser-Smith 1, T R Matthews 1
PMCID: PMC260803  PMID: 2570754

Abstract

Prophylactic treatments with either recombinant human interleukin-1 beta (rHuIL-1 beta) or a muramyl dipeptide analog ([Abu1]MDP) enhanced the resistance of mice to systemic infection with Candida albicans. The optimum treatment regimen in both normal and cyclophosphamide-treated mice was intraperitoneal administration of 100 ng of rHuIL-1 beta or 1.6 mg of [Abu1]MDP per mouse once daily for 3 consecutive days before infection. Neither rHuIL-1 beta nor [Abu1]MDP was efficacious when started after the infection or when given before cyclophosphamide to mice infected subsequently. Continuing to treat after the infection with either drug neither enhanced nor antagonized the efficacy of prophylactic treatments.

Full text

PDF
3257

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byars N. E. Two adjuvant-active muramyl dipeptide analogs induce differential production of lymphocyte-activating factor and a factor causing distress in guinea pigs. Infect Immun. 1984 May;44(2):344–350. doi: 10.1128/iai.44.2.344-350.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Czuprynski C. J., Brown J. F. Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance. Infect Immun. 1987 Sep;55(9):2061–2065. doi: 10.1128/iai.55.9.2061-2065.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dinarello C. A. Biology of interleukin 1. FASEB J. 1988 Feb;2(2):108–115. [PubMed] [Google Scholar]
  4. Fraser-Smith E. B., Eppstein D. A., Larsen M. A., Matthews T. R. Protective effect of a muramyl dipeptide analog encapsulated in or mixed with liposomes against Candida albicans infection. Infect Immun. 1983 Jan;39(1):172–178. doi: 10.1128/iai.39.1.172-178.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fraser-Smith E. B., Matthews T. R. Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice. Infect Immun. 1981 Dec;34(3):676–683. doi: 10.1128/iai.34.3.676-683.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fraser-Smith E. B., Waters R. V., Matthews T. R. Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice. Infect Immun. 1982 Jan;35(1):105–110. doi: 10.1128/iai.35.1.105-110.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fried W., Adler S. Late effects of chemotherapy on hematopoietic progenitor cells. Exp Hematol. 1985;13 (Suppl 16):49–56. [PubMed] [Google Scholar]
  8. Fuks J. Z., Patel H., Hornedo J., Van Echo D. A., Moody M., Aisner J. Infections in patients with non-small-cell lung cancer treated with intensive induction chemotherapy. Med Pediatr Oncol. 1986;14(5):255–261. doi: 10.1002/mpo.2950140504. [DOI] [PubMed] [Google Scholar]
  9. Molineux G., Xu C., Hendry J., Testa N. G. A cellular analysis of long-term haematopoietic damage in mice after repeated treatment with cyclophosphamide. Cancer Chemother Pharmacol. 1986;18(1):11–16. doi: 10.1007/BF00253055. [DOI] [PubMed] [Google Scholar]
  10. Neta R., Douches S., Oppenheim J. J. Interleukin 1 is a radioprotector. J Immunol. 1986 Apr 1;136(7):2483–2485. [PubMed] [Google Scholar]
  11. Ozaki Y., Ohashi T., Minami A., Nakamura S. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a. Infect Immun. 1987 Jun;55(6):1436–1440. doi: 10.1128/iai.55.6.1436-1440.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Phillips N. C., Chedid L. Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice. Infect Immun. 1987 Jun;55(6):1426–1430. doi: 10.1128/iai.55.6.1426-1430.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pizzo P. A., Robichaud K. J., Gill F. A., Witebsky F. G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982 Jan;72(1):101–111. doi: 10.1016/0002-9343(82)90594-0. [DOI] [PubMed] [Google Scholar]
  14. Singer C., Kaplan M. H., Armstrong D. Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med. 1977 May;62(5):731–742. doi: 10.1016/0002-9343(77)90876-2. [DOI] [PubMed] [Google Scholar]
  15. van der Meer J. W., Barza M., Wolff S. M., Dinarello C. A. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1620–1623. doi: 10.1073/pnas.85.5.1620. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES